This application is for the continuation of a NET PD clinical site at the University of Southern California. NET PD was designed to enroll patients in a series of pilot studies and clinical trials of new agents for the treatment of Parkinson's disease. The role of the clinical sites is to identify, screen, enroll, treat, and follow patients in these rials;to report data in a timely manner to the data coordinating center and to report adverse effects among enrolled patients. Currently, NET PD is conducting the LS-1 study, a multi-center, double-blind, phase III clinical trial designed to determine whether or not creatine is more effective than placebo in slowing the clinical decline in PD patients with early, treated PD. Enrollment began in 2007 and was completed on 5-28-10. All patients will be on treatment and followed for a minimum 5 years or until the end of the study. Additional exploratory trials in Parkinson's disease will be developed and conducted utilizing potential neuroprotective agents or combinations of agents over the next 5-year period as determined by the NET-PD study group and NINDS. The University of Southern California has completed 9 years of the LS-1 NET-PD study. The first subject enrolled into the LSI study on 4/30/07. A total of 55 subjects have been enrolled. Of the total enrolled, 3 have been lost to follow up, 3 have expired and the remaining 49 are active. The conduct of the study has been uneventful. Both Males and females from diverse ethnic and racial groups have been enrolled. Subjects are followed according to the protocol and in keeping with good clinical practices. Data is reported in a timely manner to the coordinating center. It is anticipated that future timelines and protocol expectations will be met on schedule.
. Disclaimer: Please note that the following critiques were prepared by the reviewers prior to the Study Section meeting and are provided in an essentially unedited form. While there is opportunity for the reviewers to update or revise their written evaluation, based upon the group's discussion, there is no guarantee that individual critiques have been updated subsequent to the discussion at the meeting. Therefore, the critiques may not fully reflect the final opinions of th individual reviewers at the close of group discussion or the final majority opinion of the group. Thus the Resume and Summary of Discussion is the final word on what the reviewers actually considered critical at the meeting.
|Wills, Anne-Marie A; Elm, Jordan J; Ye, Rong et al. (2016) Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord 33:127-133|
|Wills, Anne-Marie A; Pérez, Adriana; Wang, Jue et al. (2016) Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1 JAMA Neurol 73:321-8|
|Elm, Jordan J; NINDS NET-PD Investigators (2012) Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord 27:1513-21|